Placebo matching Daclatasvir

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Hepatitis CHepatitis C Virus (HCV)

Phase 3

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

CompletedNCT01616524

Bristol-Myers SquibbHepatitis C Virus (HCV)

Start: 2012-07-31End: 2014-09-30Updated: 2015-10-09

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

WithdrawnNCT01797848

Bristol-Myers SquibbHepatitis C

Start: 2014-06-30End: 2016-11-30Updated: 2013-11-25